OCA
KNSA icon

OpenArc Corporate Advisory’s Kiniksa Pharmaceuticals KNSA Stock Holding History

OpenArc Corporate Advisory’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-48,353
Closed -$2.33M – 820
2026
Q1 		$2.33M Buy
48,353
+14,491
+43% +$642K 0.03% 229
2025
Q4 		$1.4M Buy
+33,862
New +$1.36M 0.02% 259

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

OpenArc Corporate Advisory's KNSA Position: Q2 2026 in Review

OpenArc Corporate Advisory sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2026, closing a stake of 48,353 shares — an estimated $2.33M sold.

OpenArc Corporate Advisory first reported a position in KNSA in Q4 2025 and held it in 2 quarters. The position peaked at $2.33M in Q1 2026. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • OpenArc Corporate Advisory reported no remaining Kiniksa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • OpenArc Corporate Advisory sold 48,353 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $2.33M.
  • OpenArc Corporate Advisory first reported a position in Kiniksa Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • OpenArc Corporate Advisory's Kiniksa Pharmaceuticals position peaked at $2.33M in Q1 2026.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on OpenArc Corporate Advisory's 13F filing for Q2 2026, filed 5 Aug 2026.